Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen

Clinical Colorectal Cancer

Volumn 11, Issue 1, 2012, Pages 71-76

  Fornaro, Lorenzo ^a   Vasile, Enrico ^a   Masi, Gianluca ^a   Loupakis, Fotios ^a   Baldi, Giacomo Giulio ^a   Allegrini, Giacomo ^a   Salvatore, Lisa ^a   Cremolini, Chiara ^a   Cupini, Samanta ^b   Cortesi, Enrico ^c   Tuzi, Alessandro ^c   Granetto, Cristina ^d   Brunetti, Isa Maura ^a   Ricci, Sergio ^a   Falcone, Alfredo ^a,e  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b Azienda USL 6 di Livorno   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d S CROCE E CARLE HOSPITAL   (Italy)

^e UNIVERSITY OF PISA   (Italy)

Author keywords

5 Fluorouracil; Chemotherapy; Irinotecan; Oxaliplatin; Triplet regimen

Indexed keywords

5 FLUORO 1 METHYL 3 INDOLECARBOXYLIC ACID 3ALPHA HOMOTROPANYL ESTER; BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROPYRIMIDINE; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT SELECTION; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84861560112     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2011.06.013     Document Type: Article

References (25)

1. Fornaro L, Masi G, Loupakis F, et al. Palliative treatment of unresectable metastatic colorectal cancer. Expert Opin Pharmacother 2010; 11:63-77.
2. Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how? Br J Cancer 2009; 100:1704-19.
3. Köhne CH, Lenz HJ. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist 2009; 14:478-88.
4. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27:3677-83.
5. Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009; 27:1829-35.
6. Capdevila J, Ramos FJ, Macarulla T, et al. The role of salvage treatment in advanced colorectal cancer. Crit Rev Oncol Hematol 2009; 71:53-61.
7. Roqué I, Figuls M, Solá I, et al. Second-line chemotherapy in advanced and metastatic CRC. Cochrane Database Syst Rev 2009; (2):CD006875.
8. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22:1209-14.
9. Cunningham, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413-8.
10. Rougier P, Van Custem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407-12.
11. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21:2059-69.
12. Kim GP, Sargent DJ, Mahoney MR, et al. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol 2009; 27:2848-54.
13. Haller DG, Rothenberg ML, Wong AO, et al. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol 2008; 26:4544-50.
14. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-37.
15. Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16:1311-9.
16. Falcone A, Masi G, Allegrini G, et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002; 20:4006-14.
17. Masi G, Allegrini G, Cupini S, et al. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol 2004; 15:1766-72.
18. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25:1670-6.
19. Masi G, Vasile E, Loupakis F, et al. Randomized trial of two induction chemotherapy regimensin metastatic colorectal cancer:anupdated analysis. J Natl Cancer Inst 2011; 103:21-30.
20. Masi G, Marcucci L, Loupakis F, et al. First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. Ann Oncol 2006; 17:1249-54.
21. Gallagher DJ, Kemeny N. Second-line management of metastatic colorectal cancer. Clin Colorectal Cancer 2008; 7:25-32.
22. Goldberg RM, Rothenberg ML, Van Cutsem E et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007; 12:38-50.
23. Tabernero J, Aranda E, Gomez A, et al. Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): the MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]). J Clin Oncol 2010; 28(suppl; abstr 3501):15s.
24. Burger RA, Brady MS, Bookman MA, et al. Phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer: a Gynecologic Oncology Group (GOG) study. J Clin Oncol 2010; 28(suppl; abstr LBA1):15s.
25. Tveit K, Guren T, Glimelius B, et al. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the NORDIC VII study (NCT00145314), by the NORDIC Colorectal Cancer Biomodulation Group. Ann Oncol 2010; 21(suppl; abstr LBA20):8s.